Annovis Bio Inc (ANVS)
6.55
+0.55
(+9.17%)
USD |
NYSE |
May 31, 16:00
6.525
-0.02
(-0.38%)
Pre-Market: 20:00
Annovis Bio Cash from Financing (Quarterly): 4.415M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 4.415M |
| December 31, 2023 | 8.765M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 8.572M |
| March 31, 2023 | 0.0074M |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.0046M |
| December 31, 2021 | 0.00 |
| September 30, 2021 | -0.0255M |
| June 30, 2021 | 46.77M |
| March 31, 2021 | 0.003M |
| Date | Value |
|---|---|
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | -0.0454M |
| March 31, 2020 | 12.09M |
| December 31, 2019 | -0.0019M |
| September 30, 2019 | -0.0036M |
| June 30, 2019 | -0.0814M |
| March 31, 2019 | 0.53M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.0028M |
| March 31, 2018 | 0.2436M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.0814M
Minimum
Jun 2019
46.77M
Maximum
Jun 2021
4.023M
Average
--
Median
Sep 2020
Cash from Financing (Quarterly) Benchmarks
| ANI Pharmaceuticals Inc | -19.73M |
| Ligand Pharmaceuticals Inc | 12.18M |
| FibroGen Inc | -0.165M |
| SINTX Technologies Inc | 5.328M |
| Stereotaxis Inc | 0.03M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -7.033M |
| Free Cash Flow | -35.37M |
| Free Cash Flow Per Share (Quarterly) | -0.6497 |
| Free Cash Flow Yield | -55.80% |